AbbVie beefs up the oncology pipeline, bagging an upstart STING player with its own unique approach
AbbVie isn’t letting its $63 billion buyout of Allergan stop its M&A/deals team from continuing their work.
Monday morning we learned that the pharma giant is snapping up tiny Mavupharma out of Seattle, a Frazier-backed startup that has its own unique take on STING — which is on the threshold of their first clinical trial.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.